Yurpeak (Tirzepatide) in India: Price, Doses, Availability and How to Get It
Yurpeak is Eli Lilly's tirzepatide distributed by Cipla, launched December 2025. It costs ₹13,125 to ₹25,781 a month across six KwikPen strengths and reaches far more Indian cities than Mounjaro. The complete guide.
ALTRcare Medical Team
Clinical Editorial
Yurpeak is tirzepatide, the dual GIP and GLP-1 medication manufactured by Eli Lilly and distributed across India by Cipla under an agreement announced in October 2025, with the launch following in December 2025. It is the identical medicine to Mounjaro at the identical price: ₹13,125 a month at the 2.5 mg starting dose, rising to ₹25,781 a month at 15 mg. What Yurpeak adds is reach: Cipla's pharmacy network extends deep into tier-2 and tier-3 India, where Mounjaro stock has been patchy.
Yurpeak price list by dose (July 2026)
| Weekly dose | Per dose | Per month (4 doses) | Stage of treatment |
|---|---|---|---|
| 2.5 mg | ₹3,281 | ₹13,125 | Starting dose, weeks 1 to 4 |
| 5 mg | ₹4,101 | ₹16,406 | Early maintenance |
| 7.5 mg | About ₹5,156 | About ₹20,625 | Escalation if needed |
| 10 mg | About ₹5,156 | About ₹20,625 | Active weight loss dose |
| 12.5 mg | About ₹6,445 | About ₹25,781 | Higher maintenance |
| 15 mg | About ₹6,445 | ₹25,781 | Maximum dose |
KwikPen only
Yurpeak is sold exclusively as the KwikPen, a pre-filled multi-dose pen delivering four once-weekly doses, in all six strengths. There is no vial format for Yurpeak; if a prescription specifies vials, that is Mounjaro.
What tirzepatide does, briefly
Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, rather than GLP-1 alone. The practical effect is reduced appetite, slower stomach emptying and improved blood sugar handling. In the SURMOUNT clinical trial program, participants on higher tirzepatide doses lost around 20 percent of body weight on average over 72 weeks alongside diet and lifestyle change, more than semaglutide achieved in comparable trials. Individual results vary, and the medication is approved in India for type 2 diabetes and chronic weight management under medical supervision.
Yurpeak vs Mounjaro vs semaglutide
Yurpeak versus Mounjaro is not a medical choice: same Lilly-made medicine, same doses, same price, different distributor, so ask for whichever your pharmacy stocks. The real decision is tirzepatide versus semaglutide, and since India's March 2026 patent expiry that is largely a budget-versus-potency question: generic semaglutide starts around ₹1,290 to ₹1,800 a month, while tirzepatide starts at ₹13,125 and has no generic until Lilly's patents expire in the 2030s. Tirzepatide produces greater average weight loss in trials; semaglutide costs a tenth as much and is still highly effective. That trade-off is exactly what a doctor's consultation is for.
Yurpeak with full doctor support: ₹13,999 a month
ALTRcare's Yurpeak program includes the medication, doctor consultations, titration reviews and WhatsApp follow-up in one flat monthly price. Take the free 2-minute assessment and a doctor will confirm whether tirzepatide is right for you.
Availability: where Yurpeak actually helps
Cipla's distribution is the whole point of this brand. Mounjaro launched in March 2025 and quickly became India's top-selling drug by value, but stock concentrated in metro pharmacies. Yurpeak rides Cipla's network, one of the deepest in Indian pharma, into smaller cities and towns. If you live outside the top metros and have struggled to find tirzepatide in stock, asking your pharmacy for Yurpeak specifically is often the faster route to the same medicine.
How to get Yurpeak legally
- 1Consult a registered doctor, in person or via a legal telemedicine consultation, who reviews your BMI, medical history and blood work.
- 2Receive a valid prescription naming tirzepatide, the dose and duration, with the doctor's registration number and signature.
- 3Buy from a licensed pharmacy with cold-chain delivery; Yurpeak needs refrigeration until use.
- 4Titrate under supervision: 2.5 mg weekly for four weeks, then stepwise increases at your doctor's direction, not on your own.
Counterfeit alert
Counterfeit tirzepatide pens have circulated in India since 2025. Any Yurpeak or Mounjaro offered more than about 30 percent below MRP, without a prescription, or without cold-chain shipping should be assumed fake.
Key takeaways
- Yurpeak is Eli Lilly tirzepatide distributed by Cipla, launched December 2025, priced identically to Mounjaro.
- Monthly cost runs ₹13,125 (2.5 mg) to ₹25,781 (15 mg); most early months sit at the cheaper doses.
- It comes only as a KwikPen, in six weekly-dose strengths.
- Cipla's network makes Yurpeak the easier brand to find outside metro cities.
- It is prescription-only, needs cold-chain handling, and dose changes belong with your doctor.
Frequently asked questions
What is the price of Yurpeak in India?
Yurpeak costs ₹13,125 per month at the 2.5 mg starting dose, ₹16,406 at 5 mg, about ₹20,625 at 7.5 to 10 mg, and about ₹25,781 at 12.5 to 15 mg. Prices are identical to Mounjaro by agreement between Eli Lilly and Cipla.
Who makes Yurpeak?
Eli Lilly manufactures Yurpeak; Cipla distributes and promotes it in India under a 2025 agreement. It is the same tirzepatide as Mounjaro under a second brand name.
Is Yurpeak available as a vial?
No. Yurpeak is sold only as the KwikPen pre-filled pen, in all six strengths from 2.5 mg to 15 mg. Mounjaro is the brand that also comes in vials.
How much weight can I lose on Yurpeak?
In the SURMOUNT trials, higher tirzepatide doses produced around 20 percent average body weight loss over 72 weeks with lifestyle support. Individual results vary, and your dose and duration are decisions for your doctor.
Do I need a prescription for Yurpeak?
Yes. Yurpeak is a Schedule H prescription medicine. A registered doctor must prescribe it after assessing your eligibility, which can be done through a legal online consultation.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
